20 completed, 6 active not recruiting, 4 not yet recruiting, 3 recruiting. 23 Phase 2, 10 Phase 3, 3 Phase 1, 2 Not applicable, 1 Phase 4.
Follow OPC-67683: new trials by email Literature Review of OPC-67683 trials Research Report on OPC-67683
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A 6-Month MDR-END Plus Regimen for Rifampicin-Resistant Tuberculosis MDR-END Plus regimen, Standard-of-care (SoC) treatment - Rifampicin-Resistant Tuberculosis | Phase 3 | Not yet recruiting | Seoul National University Hospital | 294 | 2026-10-01 | 2026-06-30 |
| 6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province bedaquiline, Delamanid (DLM), Linezolid (LZD) - Treat to Target, Treatment Duration | Not applicable | Not yet recruiting | Wuhan Pulmonary Hospital | 52 | 2025-09-30 | 2025-09-30 |
| A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets JDB0131 100mg, JDB0131 200mg, Delamanid (D) - Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis | Phase 2 | Recruiting | WestVac Biopharma Co., Ltd. | 60 | 2025-09-19 | 2026-01-30 |
| A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis bedaquiline, Pretomanid (Pa), linezolid - Efficacy and Safety | Not applicable | Not yet recruiting | Wuhan Pulmonary Hospital | 200 | 2025-09-01 | 2025-08-17 |
| Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis Bedaquiline (B), Moxifloxacin, Pyrazinamide (PZA) - Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis | Phase 2 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 45 | 2025-08-20 | 2025-08-19 |
| Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort bedaquiline, delamanid, linezolid - Drug-resistant Tuberculosis, Pulmonary Tuberculosis | Phase 3 | Active not recruiting | Huashan Hospital | 120 | 2024-11-27 | 2025-09-02 |
| Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB Ganfeborole, BTZ-043, Bedaquiline (B) - Pulmonary Tuberculosis | Phase 2 | Recruiting | University College, London | 2500 | 2024-01-09 | 2026-10-15 |
| Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort Bedaquiline, Delamanid, Contezolid - Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis | Phase 3 | Active not recruiting | Beijing Chest Hospital | 186 | 2023-12-22 | 2025-04-01 |
| Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible Tuberculosis Bedaquiline (BDQ), Clofazimine (CFZ), Pyrazinamide (PZA) - Tuberculosis, Pulmonary, HIV | Phase 2 | Active not recruiting | Brigham and Women's Hospital | 94 | 2023-11-24 | 2026-08-05 |
| Short-course Regimens for the Treatment of Pulmonary Tuberculosis Rifabutin, Delamanid, Bedaquiline - Tuberculosis, Pulmonary, Tuberculosis Infection | Phase 2 / Phase 3 | Active not recruiting | Centers for Disease Control and Prevention | 288 | 2023-11-21 | 2026-09-21 |
| Clinical Study of JDB0131 Benzenesulfonate Tablets in Patients With Drug-sensitive Pulmonary Tuberculosis JDB0131, Delamanid, Ethylpyrazine rifampicide (II) - Drug-resistant Tuberculosis | Phase 2 | Unknown | Beijing Chest Hospital | 52 | 2023-10-31 | 2024-01-25 |
| BTZ-043 Dose Evaluation in Combination and Selection BTZ-043, Bedaquiline, Delamanid - Tuberculosis, Pulmonary, Other Specified Pulmonary Tuberculosis | Phase 2 | Completed | Michael Hoelscher | 92 | 2023-09-21 | 2026-10-05 |
| Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS), Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS), Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE) - Pulmonary Tuberculosis | Phase 2 | Terminated | Gates Medical Research Institute | 93 | 2023-07-26 | 2026-05-20 |
| Linezolid Dosing Strategies in Drug-Resistant TB Linezolid 600 mg, Linezolid 1200 mg (QD), Linezolid 1200 mg (TIW) - Tuberculosis, Multidrug-Resistant, Tuberculosis | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 138 | 2022-09-27 | 2026-10-02 |
| Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis GSK3036656, Bedaquiline, Delamanid - Tuberculosis | Phase 2 | Completed | GlaxoSmithKline | 127 | 2022-07-26 | 2026-06-17 |
| Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB Delamanid, Levofloxacin, Bedaquiline - Tuberculosis, Multidrug-Resistant | Phase 2 | Active not recruiting | Boston University | 271 | 2022-06-07 | 2026-07-08 |
| Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB Delamanid, Bedaquiline, RHEZ - Pulmonary TB | Phase 2 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 122 | 2022-04-12 | 2026-08-12 |
| PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE) Delpazolid, Bedaquiline, Delamanid, Moxifloxacin - Infections and Infestations, Pulmonary Tuberculosis | Phase 2 | Completed | LigaChem Biosciences, Inc. | 76 | 2021-10-28 | 2025-09-16 |
| PanACEA Sutezolid Dose-finding and Combination Evaluation Sutezolid, Bedaquiline, Delamanid, Moxifloxacin, Midazolam oral solution - Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis | Phase 2 | Completed | Michael Hoelscher | 75 | 2021-05-06 | 2023-05-01 |
| Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China Delamanid - Multidrug Resistant Tuberculosis | Phase 4 | Unknown | Beijing Chest Hospital | 608 | 2020-07-16 | 2022-07-07 |
Showing 20 of 38. Sign in to see all of them.
Tuberculosis, Multidrug-Resistant (18) · Tuberculosis, Pulmonary (18) · Tuberculosis (17) · Bacterial Infections (4) · Extensively Drug-Resistant Tuberculosis (3) · HIV Infections (3) · Mycobacterium Infections (3) · Gram-Positive Bacterial Infections (2) · Actinomycetales Infections (1) · Infections (1) · Latent Tuberculosis (1)
Otsuka Pharmaceutical Development & Commercialization, Inc. (8) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · Beijing Chest Hospital (3) · Boston University (2) · Michael Hoelscher (2) · Médecins Sans Frontières, France (2) · Seoul National University Hospital (2) · Wuhan Pulmonary Hospital (2) · Beijing Children's Hospital (1) · Brigham and Women's Hospital (1) · Centers for Disease Control and Prevention (1) · Gates Medical Research Institute (1) · GlaxoSmithKline (1) · Huashan Hospital (1) · LigaChem Biosciences, Inc. (1)
South Africa (22) · Philippines (9) · China (8) · Peru (8) · Tanzania (7) · Vietnam (5) · Haiti (4) · India (4) · Latvia (4) · Botswana (3) · Brazil (3) · Estonia (3) · South Korea (3) · Thailand (3) · Uganda (3)
Carole Mitnick, Sc.D (2) · Lorenzo Guglielmetti, MD (2) · A-Dong Shen, Master (1) · Amita Gupta, MD, MHS (1) · Andreas H Diacon, Dr. (1) · Anjanette Reyes-De Leon, MD (1) · Anneke Hesseling, MD, PhD (1) · Anthony Garcia-Prats, MD (1) · C. Robert Horsburgh, MD (1) · Charles Horsburgh, MD (1) · Constance A. Benson (1) · Daniel W Fitzgerald, MD (1) · Ekaterina V Kurbatova, MD, PhD, MPH (1) · Ethel Weld, MD (1) · Francesca M Conradie (1)
PMID 35404075, PMID 16470119, PMID 16988514, PMID 18366444, PMID 18795962, PMID 18989231, PMID 20002783, PMID 20632458, PMID 21283017, PMID 22083071, PMID 22129166, PMID 22670901, PMID 23305215, PMID 23392467, PMID 25162818, PMID 25261418, PMID 25407158, PMID 25950206, PMID 25959631, PMID 26202768, PMID 26918544, PMID 27540363, PMID 29369162, PMID 29520730, PMID 29528944, PMID 30134297, PMID 30358179, PMID 30530925, PMID 30630778, PMID 30651149, PMID 30715324, PMID 31489678, PMID 31676905, PMID 32015036, PMID 32451908, PMID 33252495, PMID 33318014, PMID 33587897, PMID 34076612, PMID 34563240, PMID 34732682, PMID 35028659, PMID 35315690, PMID 35668346, PMID 36522208, PMID 36808186, PMID 37280643, PMID 38037119, PMID 38243296, PMID 38768617
2008 (1), 2009 (1), U01AI152980 (1), U01AI170426 (1)